Characterisation of the vascular anterior surface of type 1 macular neovascularisation after anti-VEGF therapy
Conclusions
More extensive coverage of neo-CC is associated with a lower likelihood of development of macular atrophy in eyes receiving antivascular endothelial growth factor therapy, suggesting the protective effect of a type 1 MNV may be mediated by the development of a neo-CC and may provide insights into the biological significance of MNV as a response mechanism in eyes with age-related macular degeneration.
Source: British Journal of Ophthalmology - Category: Opthalmology Authors: Corvi, F., Bacci, T., Corradetti, G., Staurenghi, G., Sarraf, D., Freund, K. B., Sadda, S. Tags: Original articles - Clinical science Source Type: research
More News: Age-Related Macular Degeneration (AMD) | Eyes | Opthalmology | Science | UK Health | Vitamin A